← Browse by Condition
Medical Condition
biliary tract cancer
Total Trials
14
Recruiting Now
14
Trial Phases
Phase 3, Phase 1, Phase 2, Phase 2
Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.
Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.
The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.
Frequently Asked Questions — biliary tract cancer Clinical Trials
How many clinical trials are currently recruiting for biliary tract cancer?
ClinicalMetric currently tracks 14 actively recruiting clinical trials for biliary tract cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for biliary tract cancer?
biliary tract cancer research spans Phase 1 (3 trials), Phase 2 (7 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a biliary tract cancer clinical trial?
Eligibility criteria for biliary tract cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 7
Phase 3 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07151118
Recruiting
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
Enrollment
100 pts
Location
South Korea
Sponsor
CHA University
NCT07062263 Phase 3
Recruiting
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Enrollment
220 pts
Location
India
Sponsor
Tata Memorial Centre
NCT06428409 Phase 1, Phase 2
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Enrollment
220 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
NCT06529718 Phase 2
Recruiting
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Enrollment
72 pts
Location
France, United Kingd...
Sponsor
UNICANCER
NCT03801083 Phase 2
Recruiting
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Enrollment
59 pts
Location
United States
Sponsor
Udai Kammula
NCT07282262 Phase 2
Recruiting
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Enrollment
300 pts
Location
China
Sponsor
Peking Union Medical College H...
NCT06451497 Phase 1
Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Enrollment
100 pts
Location
United States
Sponsor
Zumutor Biologics Inc.
NCT06793709
Recruiting
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Enrollment
60 pts
Location
Japan
Sponsor
Eisai Co., Ltd.
NCT06202131
Recruiting
Use of Ctdna in Patients With Gastrointestinal Tract Tumors
Enrollment
100 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
NCT07221253 Phase 3
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Enrollment
1,100 pts
Location
United States, Austr...
Sponsor
AstraZeneca
NCT06239194 Phase 1, Phase 2
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Enrollment
285 pts
Location
United States
Sponsor
ModeX Therapeutics, An OPKO He...
NCT06731998
Recruiting
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
Enrollment
48 pts
Location
United States
Sponsor
Allegheny Singer Research Inst...
NCT07146646 Phase 2
Recruiting
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Enrollment
27 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent...
NCT06465563 Phase 2
Recruiting
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Enrollment
80 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology